Feb 9, 2026
Professional Article
Hereditary Erythrocytosis vs Polycythemia Vera: Key Differences
Learn MoreFeb 9, 2026
Professional Article
Understanding Bone Marrow Disorders: How Conditions Like Polycythemia Vera Begin
Learn MoreFeb 9, 2026
Professional Article
Myeloproliferative Neoplasms Symptoms: What Patients Experience & How They Are Assessed
Learn MoreFeb 8, 2026
Professional Article
Phlebotomy for Polycythemia Vera: Why It Lowers Risk and How It Works
Learn MoreFeb 7, 2026
Professional Article
High Red Blood Cell Count Symptoms: What They Mean and When to Worry
Learn MoreJan 30, 2026
Professional Article
Essential Thrombocythemia vs Polycythemia Vera: Understanding MPNs
Learn MoreJan 23, 2026
Newsroom
The U.S. NCCN Guidelines Included Ropeginterferon alfa-2b-njft (P1101) as a Recommended Treatment Option for Patients with Essential Thrombocythemia (ET)
Learn MoreJan 22, 2026
Professional Article
Hereditary Erythrocytosis: Primary and Secondary Forms Explained
Learn MoreJan 13, 2026
Newsroom
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
Learn MoreJan 12, 2026
Newsroom
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Learn More